PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
3.35
Dangerously high net debt exceeding 1.5x Biotechnology median of 2.02. Michael Burry would check for debt covenant compliance and refinancing risks.
-958.91
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
3.82
Current ratio 75-90% of Biotechnology median of 4.75. John Neff would demand higher margins to compensate for tighter liquidity.
No Data
No Data available this quarter, please select a different quarter.